Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar 31:2022:3284446.
doi: 10.1155/2022/3284446. eCollection 2022.

Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review

Negar Shaterian  1   2   3 , Negin Shaterian  4 , Aref Ghanaatpisheh  2   3 , Farnaz Abbasi  2   3 , Sara Daniali  2   3 , Maryam Jalali Jahromi  5   6 , Mohammad Sadegh Sanie  5   7 , Amir Abdoli  1
Affiliations
Meta-Analysis

Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review

Negar Shaterian et al. Pain Res Manag. .

Abstract

Background: Migraine is one of the most common types of headache, and it is the second most common cause of neurological disorders, with an annual prevalence of about 15% of the population. This study aimed to evaluate the effect of BoNT-A on the duration and intensity of migraine attacks. In addition, we investigated the effective injection sites.

Methods: According to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, we searched online databases, including Web of Science, PubMed, EMBASE, Scopus, Cochrane Library, ProQuest, ClinicalTrials.gov, and Google Scholar from 2011 to 2021.

Results: A total of 24 articles were included in the study. The use of BoNT-A in individuals suffering from chronic migraine (CM) decreases the frequency of migraine attacks per month, pain intensity, medication use, emergency visits, and migraine-related disabilities. The BoNT-A was well tolerated and leads to improved performance and better quality of life (QoL). Overall, treatment with BoNT-A in adults with CM is beneficial. In addition, the use of BoNT-A in individuals with vestibular migraine (VM) reduces the frequency of migraines and brings about the improvement of disability status caused by migraine headaches. Meanwhile, the use of BoNT-A reduces the frequency of migraine attacks per month among individuals with chronic refractory migraine (CRM).

Conclusions: The use of BoNT-A is a low-cost option for the treatment of various kinds of migraines, including chronic, episodic, unilateral, and vestibular types. BoNT-A can reduce the frequency of migraine attacks per month and diminish the severity of pain.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
The PRISMA flowchart of the study selection process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Øie L. R., Kurth T., Gulati S., Dodick D. W. Migraine and risk of stroke. Journal of Neurology Neurosurgery and Psychiatry . 2020;91(6):593–604. doi: 10.1136/jnnp-2018-318254. - DOI - PMC - PubMed
    1. Farhadi Z., Alidoost S., Behzadifar M., et al. The prevalence of migraine in Iran: a systematic review and meta-analysis. Iranian Red Crescent Medical Journal . 2016;18(10) doi: 10.5812/ircmj.40061.e40061 - DOI - PMC - PubMed
    1. Kim K. M., Cho S.-J., Shin H. J., et al. Prevalence, disability, and management patterns of migraine in Korea: nationwide survey data from 2009 and 2018. Journal of Clinical Neurology . 2021;17(1):p. 77. doi: 10.3988/jcn.2021.17.1.77. - DOI - PMC - PubMed
    1. Conti P., D’Ovidio C., Conti C., et al. Progression in migraine: role of mast cells and pro-inflammatory and anti-inflammatory cytokines. European Journal of Pharmacology . 2019;844:87–94. doi: 10.1016/j.ejphar.2018.12.004. - DOI - PubMed
    1. Yücel M., Kotan D., Gurol Çiftçi G., Çiftçi I. H., Cikriklar H. I. Serum levels of endocan, claudin-5 and cytokines in migraine. European Review for Medical and Pharmacological Sciences . 2016;20(5):930–936. - PubMed

Publication types

Substances